

Patient Derived Xenograft Models-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/P3BC5228ACFMEN.html>

Date: May 2018

Pages: 150

Price: US\$ 3,480.00 (Single User License)

ID: P3BC5228ACFMEN

Abstracts

Report Summary

Patient Derived Xenograft Models-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Patient Derived Xenograft Models industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Patient Derived Xenograft Models 2013-2017, and development forecast 2018-2023

Main market players of Patient Derived Xenograft Models in EMEA, with company and product introduction, position in the Patient Derived Xenograft Models market
Market status and development trend of Patient Derived Xenograft Models by types and applications

Cost and profit status of Patient Derived Xenograft Models, and marketing status

Market growth drivers and challenges

The report segments the EMEA Patient Derived Xenograft Models market as:

EMEA Patient Derived Xenograft Models Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Patient Derived Xenograft Models Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Mice Models

Rat Models

EMEA Patient Derived Xenograft Models Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Pharmaceutical & Biotechnology Companies

Contract Research Organizations

Academic & Research Institutions

EMEA Patient Derived Xenograft Models Market: Players Segment Analysis (Company
and Product introduction, Patient Derived Xenograft Models Sales Volume, Revenue,
Price and Gross Margin):

Crown Bioscience Inc. (US)

WuXi AppTec (China)

Champions Oncology, Inc. (US)

The Jackson Laboratory (US)

ONCODESIGN (France)

Charles River Laboratories International, Inc. (US)

EPO Berlin-Buch GmbH (Germany)

Shanghai LIDE Biotech Co., Ltd (China)

Xentech (France)

Horizon Discovery Group PLC (UK)

Urolead (France)

Explora BioLabs (US)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PATIENT DERIVED XENOGRAFT MODELS

- 1.1 Definition of Patient Derived Xenograft Models in This Report
- 1.2 Commercial Types of Patient Derived Xenograft Models
 - 1.2.1 Mice Models
 - 1.2.2 Rat Models
- 1.3 Downstream Application of Patient Derived Xenograft Models
 - 1.3.1 Pharmaceutical & Biotechnology Companies
 - 1.3.2 Contract Research Organizations
 - 1.3.3 Academic & Research Institutions
- 1.4 Development History of Patient Derived Xenograft Models
- 1.5 Market Status and Trend of Patient Derived Xenograft Models 2013-2023
 - 1.5.1 Asia Pacific Patient Derived Xenograft Models Market Status and Trend 2013-2023
 - 1.5.2 Regional Patient Derived Xenograft Models Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Patient Derived Xenograft Models in Asia Pacific 2013-2017
- 2.2 Consumption Market of Patient Derived Xenograft Models in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Patient Derived Xenograft Models in Asia Pacific by Regions
 - 2.2.2 Revenue of Patient Derived Xenograft Models in Asia Pacific by Regions
- 2.3 Market Analysis of Patient Derived Xenograft Models in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Patient Derived Xenograft Models in China 2013-2017
 - 2.3.2 Market Analysis of Patient Derived Xenograft Models in Japan 2013-2017
 - 2.3.3 Market Analysis of Patient Derived Xenograft Models in Korea 2013-2017
 - 2.3.4 Market Analysis of Patient Derived Xenograft Models in India 2013-2017
 - 2.3.5 Market Analysis of Patient Derived Xenograft Models in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of Patient Derived Xenograft Models in Australia 2013-2017
- 2.4 Market Development Forecast of Patient Derived Xenograft Models in Asia Pacific 2018-2023
 - 2.4.1 Market Development Forecast of Patient Derived Xenograft Models in Asia Pacific 2018-2023
 - 2.4.2 Market Development Forecast of Patient Derived Xenograft Models by Regions

2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Patient Derived Xenograft Models in Asia Pacific by Types

3.1.2 Revenue of Patient Derived Xenograft Models in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Patient Derived Xenograft Models in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Patient Derived Xenograft Models in Asia Pacific by Downstream Industry

4.2 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in Major Countries

4.2.1 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in China

4.2.2 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in Japan

4.2.3 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in Korea

4.2.4 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in India

4.2.5 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of Patient Derived Xenograft Models by Downstream Industry in Australia

4.3 Market Forecast of Patient Derived Xenograft Models in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PATIENT DERIVED XENOGRAFT MODELS

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 Patient Derived Xenograft Models Downstream Industry Situation and Trend Overview

CHAPTER 6 PATIENT DERIVED XENOGRAFT MODELS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

- 6.1 Sales Volume of Patient Derived Xenograft Models in Asia Pacific by Major Players
- 6.2 Revenue of Patient Derived Xenograft Models in Asia Pacific by Major Players
- 6.3 Basic Information of Patient Derived Xenograft Models by Major Players
 - 6.3.1 Headquarters Location and Established Time of Patient Derived Xenograft Models Major Players
 - 6.3.2 Employees and Revenue Level of Patient Derived Xenograft Models Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 PATIENT DERIVED XENOGRAFT MODELS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Crown Bioscience Inc. (US)
 - 7.1.1 Company profile
 - 7.1.2 Representative Patient Derived Xenograft Models Product
 - 7.1.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Crown Bioscience Inc. (US)
- 7.2 WuXi AppTec (China)
 - 7.2.1 Company profile
 - 7.2.2 Representative Patient Derived Xenograft Models Product
 - 7.2.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of WuXi AppTec (China)
- 7.3 Champions Oncology, Inc. (US)
 - 7.3.1 Company profile
 - 7.3.2 Representative Patient Derived Xenograft Models Product
 - 7.3.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of

Champions Oncology, Inc. (US)

7.4 The Jackson Laboratory (US)

7.4.1 Company profile

7.4.2 Representative Patient Derived Xenograft Models Product

7.4.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of The Jackson Laboratory (US)

7.5 ONCODESIGN (France)

7.5.1 Company profile

7.5.2 Representative Patient Derived Xenograft Models Product

7.5.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of ONCODESIGN (France)

7.6 Charles River Laboratories International, Inc. (US)

7.6.1 Company profile

7.6.2 Representative Patient Derived Xenograft Models Product

7.6.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Charles River Laboratories International, Inc. (US)

7.7 EPO Berlin-Buch GmbH (Germany)

7.7.1 Company profile

7.7.2 Representative Patient Derived Xenograft Models Product

7.7.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of EPO Berlin-Buch GmbH (Germany)

7.8 Shanghai LIDE Biotech Co., Ltd (China)

7.8.1 Company profile

7.8.2 Representative Patient Derived Xenograft Models Product

7.8.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Shanghai LIDE Biotech Co., Ltd (China)

7.9 Xentech (France)

7.9.1 Company profile

7.9.2 Representative Patient Derived Xenograft Models Product

7.9.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Xentech (France)

7.10 Horizon Discovery Group PLC (UK)

7.10.1 Company profile

7.10.2 Representative Patient Derived Xenograft Models Product

7.10.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Horizon Discovery Group PLC (UK)

7.11 Urolead (France)

7.11.1 Company profile

7.11.2 Representative Patient Derived Xenograft Models Product

7.11.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Urolead (France)

7.12 Explora BioLabs (US)

7.12.1 Company profile

7.12.2 Representative Patient Derived Xenograft Models Product

7.12.3 Patient Derived Xenograft Models Sales, Revenue, Price and Gross Margin of Explora BioLabs (US)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PATIENT DERIVED XENOGRAFT MODELS

8.1 Industry Chain of Patient Derived Xenograft Models

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PATIENT DERIVED XENOGRAFT MODELS

9.1 Cost Structure Analysis of Patient Derived Xenograft Models

9.2 Raw Materials Cost Analysis of Patient Derived Xenograft Models

9.3 Labor Cost Analysis of Patient Derived Xenograft Models

9.4 Manufacturing Expenses Analysis of Patient Derived Xenograft Models

CHAPTER 10 MARKETING STATUS ANALYSIS OF PATIENT DERIVED XENOGRAFT MODELS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Patient Derived Xenograft Models-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/P3BC5228ACFMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3BC5228ACFMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970